BioMarin Pharmaceutical I...
63.52
0.58 (0.92%)
At close: Dec 11, 2024, 2:43 PM
undefined%
Bid n/a
Market Cap 12.06B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) 0.7
PE Ratio (ttm) 90.74
Forward PE n/a
Analyst n/a
Ask n/a
Volume 0
Avg. Volume (20D) 14.1
Open 63.02
Previous Close 62.94
Day's Range 63.02 - 63.52
52-Week Range 58.04 - 90.70
Beta undefined

About BM8.DE

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form o...

Industry Biotechnology
Sector Healthcare
IPO Date Nov 10, 2022
Employees 3,401
Stock Exchange XETRA
Ticker Symbol BM8.DE
No News article available yet